Settings
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.24 Insider Own0.60% Shs Outstand220.46M Perf Week-3.22%
Market Cap994.27M Forward P/E- EPS next Y-0.38 Insider Trans-6.70% Shs Float219.22M Perf Month33.83%
Income-51.90M PEG- EPS next Q-0.12 Inst Own49.80% Short Float17.33% Perf Quarter3.68%
Sales34.30M P/S28.99 EPS this Y80.00% Inst Trans0.85% Short Ratio4.70 Perf Half Y-5.45%
Book/sh0.35 P/B12.89 EPS next Y-58.30% ROA-15.50% Target Price7.67 Perf Year-33.38%
Cash/sh0.85 P/C5.28 EPS next 5Y- ROE-52.40% 52W Range3.26 - 7.36 Perf YTD29.97%
Dividend- P/FCF- EPS past 5Y51.20% ROI-13.90% 52W High-38.72% Beta-0.54
Dividend %- Quick Ratio3.50 Sales past 5Y52.70% Gross Margin80.80% 52W Low38.34% ATR0.38
Employees310 Current Ratio3.70 Sales Q/Q127.80% Oper. Margin- RSI (14)47.76 Volatility5.41% 10.33%
OptionableYes Debt/Eq0.93 EPS Q/Q37.50% Profit Margin- Rel Volume0.41 Prev Close4.56
ShortableYes LT Debt/Eq0.90 EarningsFeb 25 BMO Payout- Avg Volume8.09M Price4.51
Recom2.70 SMA20-5.53% SMA504.27% SMA200-7.33% Volume3,321,609 Change-1.10%
Jan-23-15Initiated RBC Capital Mkts Sector Perform $5
Aug-07-14Reiterated WallachBeth Buy $9 → $8
Nov-15-13Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Market Perform $4.50
Oct-25-10Reiterated Barclays Capital Underweight $3 → $2
Sep-20-10Reiterated UBS Neutral $7 → $2
Sep-17-10Downgrade Davenport Buy → Neutral
Sep-14-10Downgrade Barclays Capital Equal Weight → Underweight $4 → $3
Aug-23-10Reiterated UBS Neutral $3.50 → $7
Jul-16-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1
Jul-02-10Reiterated UBS Buy $40 → $38
Feb-04-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
Dec-17-09Initiated Jefferies & Co Hold $4
Sep-21-09Downgrade Leerink Swann Outperform → Mkt Perform $6
Sep-18-09Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $3
Sep-15-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Aug-18-09Initiated JMP Securities Mkt Perform
Jun-24-09Initiated Rodman & Renshaw Mkt Outperform $9
Mar-16-09Downgrade Canaccord Adams Hold → Sell
Feb-18-09Downgrade UBS Buy → Neutral $6 → $7
Jan-29-15 08:54AM  An Early Version Of Samsung's Next Galaxy Phone Might Have Just Leaked Business Insider
Jan-23-15 04:52PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
11:49AM  Brazil's $3 Billion World Cup Stadiums Are Turning Into White Elephants 6 Months Later Business Insider
06:18AM  Coverage initiated on Arena Pharm by RBC Capital Mkts Briefing.com
06:00AM  Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics at TheStreet
Jan-22-15 04:00PM  Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Zacks
Jan-21-15 05:45PM  Stock Pops & Drops: CHL, ARNA, MBLY & ANTM CNBC -10.96%
03:10PM  Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following Equity Offering; Insperity Shares Spike Higher Benzinga
10:42AM  Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit Tops Expectations Benzinga
08:45AM  Arena Pharmaceuticals Announces Agreement to Sell Common Stock Benzinga
08:45AM  Arena Pharmaceuticals Announces Agreement to Sell Common Stock PR Newswire
Jan-20-15 05:16PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events EDGAR Online
04:04PM  Arena Pharmaceuticals Announces Public Offering of Common Stock PR Newswire
12:34PM  Did you know Arena Pharmaceuticals is a CAR-T company? Neither did I. Next week, it will be gene therapy. I guess anything is better than being known for peddling a mediocre weight loss pill with disappointing fourth-quarter sales . Yahoo Finance Contributors
Jan-16-15 02:20PM  Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog Zacks
Jan-15-15 09:57AM  Can the Uptrend Continue for Arena Pharma (ARNA)? - Tale of the Tape Zacks -8.29%
Jan-14-15 01:55PM  5 Obesity Stocks Investors Are Watching Benzinga -6.28%
09:00AM  Indie Game Developer Eforb Launches Game Publishing Service: Gamebox Arena CNW Group
Jan-12-15 04:21PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
08:00AM  Arena Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Ralinepag for Pulmonary Arterial Hypertension PR Newswire
Jan-09-15 08:00AM  Arena Pharmaceuticals Reports on Eisai's New Marketing Initiatives for BELVIQ® (lorcaserin HCl) CIV PR Newswire -5.73%
07:32AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
Jan-07-15 01:00PM  Midday movers: Alkermes, Lennar, Radian Group & more at CNBC +76.20%
12:30PM  Arena Pharma surges on data from autoimmune drug study AP
08:00AM  Arena Pharmaceuticals Reports Positive Results from Phase 1b Clinical Trial Evaluating APD334 for the Treatment of Autoimmune Diseases PR Newswire
Jan-06-15 08:00AM  Arena Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference PR Newswire -5.68%
Dec-23-14 04:49PM  FDA clears Novo Nordisk's weight loss drug Saxenda AP -5.79%
Dec-19-14 02:09PM  Orexigen Therapeutics Gains On Diet Pill Nod From European Committee Benzinga
Dec-12-14 11:58AM  Obesity Pill Upstart Orexigen Therapeutics Gaining on Rivals Yahoo Finance Blogs
Dec-05-14 05:26PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Nov-25-14 08:00AM  Arena Pharmaceuticals Issued Composition of Matter Patent by United States Patent and Trademark Office for Ralinepag and Related Compounds PR Newswire
Nov-24-14 08:00AM  Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference PR Newswire
Nov-14-14 01:04PM  ARENA PHARMACEUTICALS INC Financials EDGAR Online Financials
Nov-13-14 12:10PM  What's Driving Orexigen Therapeutics Higher? Benzinga
08:00AM  Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference PR Newswire
06:28AM  Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? Zacks
Nov-08-14 07:07PM  10-Q for Arena Pharmaceuticals, Inc. Company Spotlight
Nov-06-14 04:57PM  ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
08:00AM  Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases PR Newswire
Nov-05-14 08:00AM  Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference PR Newswire
Nov-04-14 08:30AM  Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows Zacks
Nov-03-14 02:40PM  Arena Pharma's 'Belviq' potential CNBC
08:37AM  Arena Pharmaceuticals Reports Q3 Loss, Shares Surge 6% Benzinga
07:31AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial EDGAR Online
07:27AM  Arena Pharmaceuticals tops 3Q profit forecasts AP
07:07AM  Q3 2014 Arena Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
06:45AM  Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results PR Newswire
06:30AM  Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation PR Newswire
Oct-31-14 03:20PM  Will Arena Pharma (ARNA) Q3 Loss Be Wider than Expected? Zacks
08:00AM  Lorcaserin Data to be Presented at The Obesity Society's Annual Scientific Meeting PR Newswire
06:40AM  Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx at TheStreet
Oct-30-14 09:19AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Oct-29-14 07:30AM  Arena Skimps on Data Disclosure From Weight-Loss Combo Study at TheStreet
Oct-28-14 06:20PM  Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot Study of Coadministration of Lorcaserin HCl and Phentermine HCl PR Newswire
Oct-27-14 08:00AM  Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3 PR Newswire
Oct-20-14 04:58PM  Bank Of America Q3 Small & Mid-Cap Biotech Preview Benzinga
Oct-13-14 08:00AM  Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College of Clinical Pharmacy Annual Meeting PR Newswire
Oct-10-14 11:36AM  Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine PR Newswire
Oct-09-14 04:41PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ EDGAR Online
Oct-02-14 12:10PM  Zafgen Aims Obesity Drug At Rare, Deadly Disease at Forbes
Sep-30-14 10:37AM  [video] Zafgen CEO: 2015 Will Be Data Rich Year for Obesity Treatment at TheStreet
Sep-22-14 08:00AM  Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference PR Newswire
Sep-19-14 06:43AM  Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% Zacks
Sep-16-14 09:48AM  Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy at TheStreet
Sep-11-14 05:15PM  [video] Orexigen drops in spite of FDA approval at CNBC
04:00PM  U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Reuters
01:23PM  Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised at TheStreet
08:37AM  Pharmalot, Pharmalittle: We're Reading About Orexigen, Allergan and Lots More!! at The Wall Street Journal
07:18AM  FDA approves weight-loss drug Contrave AP
Sep-10-14 09:16PM  New Drug to Treat Obesity Gains Approval by F.D.A. at New York Times
07:58PM  FDA Approves Contrave Weight Loss Drug From Orexigen And Takeda at Forbes
07:00PM  Orexigen Wins U.S. FDA Approval for Weight-Loss Pill at Bloomberg
08:00AM  Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium PR Newswire
Sep-09-14 09:32AM  FDA staff: Novo Nordisk drug liraglutide effective for obesity Reuters
Sep-03-14 04:20PM  Arena Pharmaceuticals' APD811 Gets Orphan Drug Status Zacks
11:50AM  Credit Suisse Positive on Some Biotechs, Very Cautious on Others at 24/7 Wall St.
Sep-02-14 08:00AM  Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension PR Newswire
Aug-19-14 10:45AM  You've got obesity all wrong: Zafgen CEO at CNBC
Aug-18-14 06:26AM  [video] Obesity treatment sales fall short at CNBC
Aug-06-14 04:34PM  ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Aug-04-14 10:10AM  Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss Zacks
Aug-01-14 08:18AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
07:07AM  Q2 2014 Arena Pharmaceuticals Earnings Release - After Market Close CCBN
04:30AM  Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results PR Newswire
Jul-31-14 06:00AM  'Mad Money' Lightning Round: Stay With Thermo Fisher Scientific at TheStreet
Jul-30-14 08:00AM  Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity PR Newswire
Jul-29-14 08:00AM  Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category PR Newswire
Jul-25-14 03:51PM  Arena Sees Belviq Sales Climb Despite Seasonality at Seeking Alpha
08:00AM  Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 PR Newswire
Jul-21-14 04:33PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
08:11AM  Arena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary theflyonthewall.com
08:00AM  Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) in Israel PR Newswire
Jul-19-14 04:14PM  The Implications of Obesity as a Disability in Europe at Motley Fool
Jul-18-14 02:10PM  Arena Stock Rises With Expected Jump In Belviq Sales at Seeking Alpha
Jul-16-14 03:30PM  Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent Zacks
11:20AM  Arena Gives Pipeline Exposure - Is The Company Partner Shopping? at Seeking Alpha
Jul-15-14 06:50PM  Arena Pharmaceuticals Inc. Still Down After CEO's Sale at Motley Fool
04:34PM  Arena Pharmaceuticals granted patent for Cannabinoid Receptor Modulators theflyonthewall.com
04:31PM  Arena Pharmaceuticals Issued Patent for APD371 by United States Patent and Trademark Office PR Newswire
01:10PM  Fed Chair Yellen Says Small Biotech Stocks Over-Valued at TheStreet
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company's products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug products under a manufacturing services agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPECTOR STEVEN WEVP, General Counsel & SecJan 08Option Exercise6.1645,000277,200173,039Jan 08 09:08 PM
SPECTOR STEVEN WEVP, General Counsel & SecJan 08Sale6.2645,000281,700128,039Jan 08 09:08 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerJan 07Option Exercise1.4950,00074,500100,000Jan 08 09:07 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerJan 07Sale5.4950,000274,50050,000Jan 08 09:07 PM
LIEF JACKChairman, President and CEOSep 17Option Exercise1.49100,000149,000441,039Sep 19 04:50 PM
LIEF JACKChairman, President and CEOJul 01Sale5.85223,5251,308,582361,039Jul 03 04:38 PM
BELCHER DONALD DDirectorJun 27Option Exercise5.462,47313,50396,585Jun 27 06:49 PM
BELCHER DONALD DDirectorJun 27Sale5.852,47314,46794,112Jun 27 06:49 PM
SPECTOR STEVEN WEVP, General Counsel & SecMay 12Option Exercise1.4945,00067,050147,187May 14 07:34 PM
SPECTOR STEVEN WEVP, General Counsel & SecMay 12Sale7.0545,000317,358102,187May 14 07:34 PM
BELCHER DONALD DDirectorMay 06Option Exercise4.314,17617,99972,904May 07 07:54 PM
BELCHER DONALD DDirectorMay 06Sale7.004,17629,23268,728May 07 07:54 PM
HIXSON HARRY F JRDirectorApr 22Option Exercise4.1136,900151,659119,776Apr 24 06:14 PM
HIXSON HARRY F JRDirectorApr 22Sale6.3136,900232,75482,876Apr 24 06:14 PM
Nova Tina SusanDirectorApr 14Option Exercise4.7035,000164,35053,728Apr 15 09:59 PM
Nova Tina SusanDirectorApr 14Sale6.2235,000217,76318,728Apr 15 09:59 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerApr 01Option Exercise6.3060,000378,00095,000Apr 02 08:35 PM
BELCHER DONALD DDirectorApr 01Option Exercise6.301,90512,00270,633Apr 02 08:34 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerApr 01Sale6.3760,000382,01435,000Apr 02 08:35 PM
BELCHER DONALD DDirectorApr 01Sale6.451,90512,28768,728Apr 02 08:34 PM
SPECTOR STEVEN WEVP, General Counsel & SecMar 04Option Exercise1.4925,00037,250126,794Mar 05 08:03 PM
SPECTOR STEVEN WEVP, General Counsel & SecMar 04Sale7.0125,000175,250101,794Mar 05 08:03 PM